/

CORT

Corcept Therapeutics IncorporatOpen

119.94−1.26 −1.04%USD

NasdaqCM · as of Oct 13, 10:18 ET · 15m delay

Open

121.83

Prev close

121.19

Day range

118.71122.81

52-week range

28.66126.38

Volume

88.87K0.07×

Mkt cap

12.96B

P/E ttm

266.52

Fwd P/E

27.24

EPS ttm

0.4500

Div yield

0.00%

Earnings

Jul 29, 2026

From 52w high

−5.10%

Price Chart

Yahoo Finance · delayed

CORTOct 13, 2026O 121.83H 122.81L 118.71C 119.93−1.26 (−1.04%)Vol 88.87K

SMA 50115.46
SMA 20071.24

1Y change +62.16% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CORT Corcept Therapeutics Incorporat · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +0.31%
1 month: +6.33%
3 months: +32.57%
6 months: +174.58%
Year to date: +244.64%
1 year: +67.67%

Valuation & ownership

Market cap: 12.96B
Enterprise value: 12.80B
P/E (ttm): 266.52
Forward P/E: 27.24
PEG ratio: 0.81
Price / book: 18.34
Price / sales (ttm): 15.60
EV / EBITDA: 1583.58
EPS (ttm): 0.4500
EPS (forward): 4.40
Beta (5y monthly): 0.40
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 108.10M
Float: 96.39M
Short % of float: 10.18%
Short ratio (days): 5.11
Held by insiders: 11.46%
Held by institutions: 76.92%
Avg volume (3m): 1.27M
50-day average: 115.31
200-day average: 71.06
52-week change: +67.67%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 56.6
vs 50-day SMA: +3.88%
vs 200-day SMA: +68.36%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 4.16%
Realised vol (20d, ann.): 40.7%
From 52-week high: −5.10%
From 52-week low: +318.48%

ANR

Analyst Consensus

5 analysts

Consensus

Buy

2.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

141.00

+17.56% implied

Low 50.00Median 164.00High 165.00

Recommendation trend

Now4 / 0 / 1
1m ago4 / 0 / 1

DES

About Corcept Therapeutics Incorporat

Yahoo Finance profile

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 730
Headquarters: Redwood City, CA, United States
Website: corcept.com
Officers: Dr. Joseph K. Belanoff M.D. Co-Founder, President, CEO & Director
Mr. Atabak Mokari CFO & Treasurer
Dr. William Guyer Pharm.D. Chief Development Officer

SEAS

Seasonality · CORT

2007–2026 · monthly returns

Strongest month Mar +15.13%Weakest month Apr −0.16%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	14.6	-10.5	12.9	15.4	49.4	25.1	31.7	-1.0	1.7	4.1			+244.6%
2025	32.8	-9.5	88.5	-37.1	7.9	-5.4	-8.5	3.8	19.2	-11.6	8.1	-56.2	−30.9%
2024	-35.0	11.4	7.2	-7.4	29.4	7.7	19.0	-8.7	31.1	5.8	17.8	-12.6	+55.1%
2023	12.6	-8.9	4.0	4.0	4.3	-5.3	14.5	28.5	-16.7	3.0	-9.3	27.5	+59.9%
2022	-5.2	18.8	1.0	-4.5	-3.1	14.1	20.5	-9.9	-0.7	11.5	-11.6	-19.7	+2.6%
2021	8.0	-11.0	-5.4	-4.2	-5.2	1.9	-5.6	2.5	-7.5	-8.5	16.7	-5.7	−24.3%
2020	4.7	-0.4	-5.8	6.5	19.6	11.1	-11.1	-15.1	37.1	-3.6	34.9	15.5	+116.2%
2019	-16.3	11.5	-5.9	5.5	-21.0	14.0	1.0	12.0	12.1	3.2	-12.1	-5.7	−9.4%
2018	27.5	-34.0	8.3	1.4	10.9	-15.0	-16.5	14.4	-6.7	-16.2	18.6	-4.1	−26.0%
2017	-2.1	26.4	21.9	-13.0	18.6	4.3	5.7	33.7	15.8	2.0	-8.9	0.7	+148.8%
2016	-26.7	4.7	22.5	1.9	24.7	-8.2	6.2	-8.1	22.0	6.8	20.9	-13.5	+45.8%
2015	-3.0	13.7	69.2	3.0	6.1	-1.8	-16.1	-0.8	-24.8	-1.9	43.1	-5.7	+66.0%
2014	7.2	-4.7	32.9	1.4	-48.9	23.9	-14.6	15.5	-2.9	21.3	-6.8	-1.0	−6.5%
2013	51.7	-24.4	22.0	-11.5	2.8	-4.9	22.0	-21.3	-4.2	6.3	27.2	49.3	+124.5%
2012	0.3	14.6	0.0	-4.8	9.4	9.8	-19.4	-20.2	-3.5	-10.4	-42.4	-0.7	−58.2%
2011	4.9	-7.7	13.6	3.5	12.3	-19.2	-10.3	-20.9	9.5	2.3	-0.3	8.2	−11.4%
2010	-7.9	9.4	1.8	18.6	-4.4	-3.4	4.2	-14.2	39.4	-8.2	9.2	-1.0	+38.8%
2009	-21.6	42.5	4.4	-25.2	-1.1	-8.0	39.5	-2.7	36.4	34.7	10.9	24.1	+172.5%
2008	-14.9	-2.3	25.3	-13.4	-16.1	-16.2	-5.1	0.0	-30.6	2.3	-22.7	0.0	−67.0%
2007	-0.8	-9.8	-18.2	72.2	-10.3	97.1	-17.9	42.7	52.6	-25.9	-18.7	4.7	+151.2%

INSD

Insider Activity · CORT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

1.87M shares

Sells, 6 months

857.3K shares

Net shares

+1.02M

Net change in insider shares

+8.90%

Date	Insider	Transaction	Shares	Value
Oct 1, 2026	Maduck SeanOfficer	Sale at price 115.54 - 116.55 per share.	25K	$2.91M
Oct 1, 2026	Maduck SeanOfficer	Conversion of Exercise of derivative security at price 8.27 per share.	25K	$206.75K
Oct 1, 2026	Lyon Joseph DouglasChief Technology Officer	Sale at price 115.40 - 116.54 per share.	10K	$1.16M
Oct 1, 2026	Lyon Joseph DouglasChief Technology Officer	Conversion of Exercise of derivative security at price 13.56 - 19.26 per share.	10K	$168.85K
Oct 1, 2026	Vieira Roberto WOfficer	Sale at price 114.52 - 116.58 per share.	8.3K	$967.45K
Oct 1, 2026	Vieira Roberto WOfficer	Conversion of Exercise of derivative security at price 21.63 per share.	8.3K	$180.24K
Sep 23, 2026	Robb Gary CharlesOfficer	Stock Gift at price 0.00 per share.	17.1K	—
Sep 14, 2026	Wilson James NDirector	Sale at price 110.27 - 111.70 per share.	10K	$1.11M
Sep 13, 2026	Lyon Joseph DouglasChief Technology Officer	Sale at price 113.32 - 114.12 per share.	10K	$1.13M
Sep 13, 2026	Lyon Joseph DouglasChief Technology Officer	Conversion of Exercise of derivative security at price 11.35 - 13.56 per share.	10K	$129.86K
Sep 1, 2026	Vieira Roberto WOfficer	Sale at price 109.35 - 115.44 per share.	58.3K	$6.46M
Sep 1, 2026	Vieira Roberto WOfficer	Conversion of Exercise of derivative security at price 21.63 per share.	58.3K	$1.26M
Aug 31, 2026	Robb Gary CharlesOfficer	Stock Award(Grant) at price 0.00 - 113.38 per share.	328	$18.59K
Aug 31, 2026	Mokari AtabakChief Financial Officer	Stock Award(Grant) at price 0.00 - 113.38 per share.	276	$15.65K
Aug 31, 2026	Maduck SeanOfficer	Stock Award(Grant) at price 0.00 - 113.38 per share.	300	$17.01K
Aug 31, 2026	Maduck SeanOfficer	Sale at price 113.94 - 115.61 per share.	25K	$2.86M
Aug 31, 2026	Maduck SeanOfficer	Conversion of Exercise of derivative security at price 8.27 per share.	25K	$206.75K
Aug 31, 2026	Lyon Joseph DouglasChief Technology Officer	Stock Award(Grant) at price 0.00 - 113.38 per share.	260	$14.74K
Aug 31, 2026	Guyer WilliamOfficer	Stock Award(Grant) at price 0.00 - 113.38 per share.	328	$18.59K
Aug 31, 2026	Vieira Roberto WOfficer	Stock Award(Grant) at price 0.00 - 113.38 per share.	276	$15.65K

13F

Investors Holding CORT

latest 13F filings of 29 followed managers

Investors holding CORT
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$457.5M	0.63%	5.26M	−7.4%	Q2 2026
Bridgewater Associates · Ray Dalio	$5.0M	0.02%	57.60K	+50%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

CORT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CORT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Corcept Therapeutics Incorporat

Seasonality · CORT

Insider Activity · CORT

Congress Trades · CORT

Investors Holding CORT

Investors Holding CORT

Congress Trades · CORT

Insider Activity · CORT

Seasonality · CORT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Corcept Therapeutics Incorporat

Financial Snapshot

Earnings & Dividends

News